GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » Current Ratio

Centogene NV (Centogene NV) Current Ratio : 1.45 (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Centogene NV Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Centogene NV's current ratio for the quarter that ended in Jun. 2023 was 1.45.

Centogene NV has a current ratio of 1.45. It generally indicates good short-term financial strength.

The historical rank and industry rank for Centogene NV's Current Ratio or its related term are showing as below:

CNTG' s Current Ratio Range Over the Past 10 Years
Min: 0.56   Med: 1.62   Max: 2.48
Current: 1.45

During the past 7 years, Centogene NV's highest Current Ratio was 2.48. The lowest was 0.56. And the median was 1.62.

CNTG's Current Ratio is ranked worse than
70.59% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.245 vs CNTG: 1.45

Centogene NV Current Ratio Historical Data

The historical data trend for Centogene NV's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV Current Ratio Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial 1.18 2.35 1.70 1.28 2.43

Centogene NV Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 2.48 2.39 2.43 1.45

Competitive Comparison of Centogene NV's Current Ratio

For the Diagnostics & Research subindustry, Centogene NV's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centogene NV's Current Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's Current Ratio distribution charts can be found below:

* The bar in red indicates where Centogene NV's Current Ratio falls into.



Centogene NV Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Centogene NV's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=63.381/26.128
=2.43

Centogene NV's Current Ratio for the quarter that ended in Jun. 2023 is calculated as

Current Ratio (Q: Jun. 2023 )=Total Current Assets (Q: Jun. 2023 )/Total Current Liabilities (Q: Jun. 2023 )
=42.157/29.146
=1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centogene NV  (NAS:CNTG) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Centogene NV Current Ratio Related Terms

Thank you for viewing the detailed overview of Centogene NV's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Centogene NV (Centogene NV) Business Description

Traded in Other Exchanges
Address
Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.